Skip to main content
main-content

12.04.2022 | Original Article

Efficacy and safety of a thermal fractional skin rejuvenation system (Tixel) for the treatment of facial and/or scalp actinic keratoses

verfasst von: Meital Oren-Shabtai, Nadezhda Sloutsky, Moshe Lapidoth, Daniel Mimouni, Ilia Chorny, Igor Snast, Yael Anne Leshem, Rivka Friedland, Emmilia Hodak, Ifat Klein, Yael Agmon, Assi Levi

Erschienen in: Lasers in Medical Science

Einloggen, um Zugang zu erhalten

Abstract

Actinic keratoses are common cutaneous lesions with a potential to progress to invasive squamous cell carcinoma. Therefore, treatment is crucial. The Tixel® is a noninvasive thermomechanical device designed to transfer heat to the upper dermis in a controlled manner according to a predetermined setting. This study aimed to evaluate the safety and efficacy of a thermomechanical fractional skin resurfacing technology for the treatment of facial and scalp actinic keratoses. A prospective, open-label, before–after study was conducted in a tertiary medical centre from May 2020 to April 2021. Patients presenting with facial/scalp actinic keratoses of mild-to-moderate thickness underwent 2 or 3 Tixel treatments (depending on clinical improvement), 3–4 weeks apart. The reduction in lesion count and overall improvement in appearance were assessed by clinical examination and digital photography. Findings were compared between baseline and follow-up at 3 months after the last treatment session. Patient satisfaction was evaluated by questionnaire, and adverse effects were documented. A total of 20 patients participated in the study. All completed 2–3 treatments and follow-up visits. Assessment of digital photographs was performed by 2 assessors blinded to the timepoint at which each photo was taken (before or after treatment). The average number of lesions at baseline was 9.8 (± 4.8) and the mean reduction in lesion count was 7.9 (± 4.4) (80.6%). Complete clearance was observed in 31.6% of patients. No adverse effects were noted during treatment and follow-up. Most patients reported being “very satisfied” or “satisfied” with the treatment results (85%) and experience (95%). Treating facial and scalp actinic keratoses with the Tixel device was found to be effective and safe.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Warino L, Tusa M, Camacho F, Teuschler H, Fleischer AB Jr, Feldman SR (2006) Frequency and cost of actinic keratosis treatment. Dermatol Surg 32(8):1045–1049 PubMed Warino L, Tusa M, Camacho F, Teuschler H, Fleischer AB Jr, Feldman SR (2006) Frequency and cost of actinic keratosis treatment. Dermatol Surg 32(8):1045–1049 PubMed
2.
Zurück zum Zitat Flohil SC, van der Leest RJ, Dowlatshahi EA, Hofman A, de Vries E, Nijsten T (2013) Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study. J Investig Dermatol 133(8):1971–1978 CrossRef Flohil SC, van der Leest RJ, Dowlatshahi EA, Hofman A, de Vries E, Nijsten T (2013) Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study. J Investig Dermatol 133(8):1971–1978 CrossRef
3.
Zurück zum Zitat Marks R, Rennie G, Selwood TS (1988) Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet Lond Engl 1(8589):795–797 CrossRef Marks R, Rennie G, Selwood TS (1988) Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet Lond Engl 1(8589):795–797 CrossRef
4.
Zurück zum Zitat Glogau RG (2000) The risk of progression to invasive disease. J Am Acad Dermatol 42(1 Pt 2):23–24 CrossRef Glogau RG (2000) The risk of progression to invasive disease. J Am Acad Dermatol 42(1 Pt 2):23–24 CrossRef
5.
Zurück zum Zitat Dianzani C, Conforti C, Giuffrida R, Corneli P, di Meo N, Farinazzo E et al (2020) Current therapies for actinic keratosis. Int J Dermatol 59(6):677–684 CrossRef Dianzani C, Conforti C, Giuffrida R, Corneli P, di Meo N, Farinazzo E et al (2020) Current therapies for actinic keratosis. Int J Dermatol 59(6):677–684 CrossRef
6.
Zurück zum Zitat Cramer P, Stockfleth E (2020) Actinic keratosis: where do we stand and where is the future going to take us? Expert Opin Emerg Drugs 25(1):49–58 CrossRef Cramer P, Stockfleth E (2020) Actinic keratosis: where do we stand and where is the future going to take us? Expert Opin Emerg Drugs 25(1):49–58 CrossRef
7.
Zurück zum Zitat Werner RN, Stockfleth E, Connolly SM, Correia O, Erdmann R, Foley P, International League of Dermatological Societies, European Dermatology Forum et al (2015) Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version. J Eur Acad Dermatol Venereol 29(11):2069–79 CrossRef Werner RN, Stockfleth E, Connolly SM, Correia O, Erdmann R, Foley P, International League of Dermatological Societies, European Dermatology Forum et al (2015) Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version. J Eur Acad Dermatol Venereol 29(11):2069–79 CrossRef
8.
Zurück zum Zitat Ianhez M, Miot HA, Bagatin E (2014) Liquid nitrogen for the treatment of actinic keratosis: a longitudinal assessment. Cryobiology 69(1):140–143 CrossRef Ianhez M, Miot HA, Bagatin E (2014) Liquid nitrogen for the treatment of actinic keratosis: a longitudinal assessment. Cryobiology 69(1):140–143 CrossRef
9.
Zurück zum Zitat Marmur ES, Schmults CD, Goldberg DJ (2004) A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatologic Surg 30(2 Pt 2):264–271 Marmur ES, Schmults CD, Goldberg DJ (2004) A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatologic Surg 30(2 Pt 2):264–271
10.
Zurück zum Zitat Chetty P, Choi F, Mitchell T (2015) Primary care review of actinic keratosis and its therapeutic options: a global perspective. Dermatol Ther (Heidelb) 5(1):19–35 CrossRef Chetty P, Choi F, Mitchell T (2015) Primary care review of actinic keratosis and its therapeutic options: a global perspective. Dermatol Ther (Heidelb) 5(1):19–35 CrossRef
11.
Zurück zum Zitat Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E (2007) A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses:a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 157(Suppl 2):34–40 CrossRef Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E (2007) A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses:a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 157(Suppl 2):34–40 CrossRef
12.
Zurück zum Zitat Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y (2002) Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 146(1):94–100 CrossRef Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y (2002) Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 146(1):94–100 CrossRef
13.
Zurück zum Zitat Berman B, Amini S (2012) Pharmacotherapy of actinic keratosis: an update. Expert Opin Pharmacother 13(13):1847–1871 CrossRef Berman B, Amini S (2012) Pharmacotherapy of actinic keratosis: an update. Expert Opin Pharmacother 13(13):1847–1871 CrossRef
14.
Zurück zum Zitat Dirschka T, Peris K, Gupta G, Alomar A, Aractingi S, Dakovic R et al (2016) Imiquimod 3.75% in actinic keratosis: efficacy in patients with and without rest periods during treatment. J Eur Acad Dermatol Venereol. 30(8):1416–7 CrossRef Dirschka T, Peris K, Gupta G, Alomar A, Aractingi S, Dakovic R et al (2016) Imiquimod 3.75% in actinic keratosis: efficacy in patients with and without rest periods during treatment. J Eur Acad Dermatol Venereol. 30(8):1416–7 CrossRef
15.
Zurück zum Zitat Stockfleth E, Gupta G, Peris K, Aractingi S, Dakovic R, Alomar A (2014) Reduction in lesions from Lmax: a new concept for assessing efficacy of field-directed therapy for actinic keratosis. Results with imiquimod 3.75%. Eur J Dermatol. 24(1):23–7 CrossRef Stockfleth E, Gupta G, Peris K, Aractingi S, Dakovic R, Alomar A (2014) Reduction in lesions from Lmax: a new concept for assessing efficacy of field-directed therapy for actinic keratosis. Results with imiquimod 3.75%. Eur J Dermatol. 24(1):23–7 CrossRef
16.
Zurück zum Zitat Lacour JP, Ulrich C, Gilaberte Y, Von Felbert V, Basset-Seguin N, Dreno B et al (2015) Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. J Eur Acad Dermatol Venereol 29:2342–2348 CrossRef Lacour JP, Ulrich C, Gilaberte Y, Von Felbert V, Basset-Seguin N, Dreno B et al (2015) Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. J Eur Acad Dermatol Venereol 29:2342–2348 CrossRef
17.
Zurück zum Zitat Enk CD, Levi A (2012) Low-irradiance red LED traffic lamps as light source in PDT for actinic keratoses. Photodermatol Photoimmunol Photomed 28(6):332–334 CrossRef Enk CD, Levi A (2012) Low-irradiance red LED traffic lamps as light source in PDT for actinic keratoses. Photodermatol Photoimmunol Photomed 28(6):332–334 CrossRef
18.
Zurück zum Zitat Damian DL (2017) Nicotinamide for skin cancer chemoprevention. Australas J Dermatol 58(3):174–180 CrossRef Damian DL (2017) Nicotinamide for skin cancer chemoprevention. Australas J Dermatol 58(3):174–180 CrossRef
19.
Zurück zum Zitat Sharon E, Snast I, Lapidoth M, Kaftory R, Mimouni D, Hodak E et al (2021) Laser Treatment for non-melanoma skin cancer: a systematic review and meta-analysis. Am J Clin Dermatol 22(1):25–38 CrossRef Sharon E, Snast I, Lapidoth M, Kaftory R, Mimouni D, Hodak E et al (2021) Laser Treatment for non-melanoma skin cancer: a systematic review and meta-analysis. Am J Clin Dermatol 22(1):25–38 CrossRef
20.
Zurück zum Zitat Trimas SJ, Ellis DA, Metz RD (1997) The carbon dioxide laser. An alternative for the treatment of actinically damaged skin. Dermatol Surg 23(10):885–9 CrossRef Trimas SJ, Ellis DA, Metz RD (1997) The carbon dioxide laser. An alternative for the treatment of actinically damaged skin. Dermatol Surg 23(10):885–9 CrossRef
21.
Zurück zum Zitat Fulton JE, Rahimi AD, Helton P, Dahlberg K, Kelly AG (1999) Disappointing results following resurfacing of facial skin with CO2 lasers for prophylaxis of keratoses and cancers. Dermatol Surg 25(9):729–732 CrossRef Fulton JE, Rahimi AD, Helton P, Dahlberg K, Kelly AG (1999) Disappointing results following resurfacing of facial skin with CO2 lasers for prophylaxis of keratoses and cancers. Dermatol Surg 25(9):729–732 CrossRef
22.
Zurück zum Zitat Elman M, Fournier N, Barnéon G, Bernstein EF, Lask G (2016) Fractional treatment of aging skin with Tixel, a clinical and histological evaluation. J Cosmet Laser Ther 18(1):31–37 PubMed Elman M, Fournier N, Barnéon G, Bernstein EF, Lask G (2016) Fractional treatment of aging skin with Tixel, a clinical and histological evaluation. J Cosmet Laser Ther 18(1):31–37 PubMed
24.
Zurück zum Zitat Kokolakis G, Von Grawert L, Ulrich M, Lademann J, Zuberbier T, Hofmann MA (2020) Wound healing process after thermomechanical skin ablation. Lasers Surg Med 52(8):730–734 CrossRef Kokolakis G, Von Grawert L, Ulrich M, Lademann J, Zuberbier T, Hofmann MA (2020) Wound healing process after thermomechanical skin ablation. Lasers Surg Med 52(8):730–734 CrossRef
25.
Zurück zum Zitat Shavit R, Dierickx C (2020) A new method for percutaneous drug delivery by thermo-mechanical fractional injury. Lasers Surg Med 52(1):61–69 CrossRef Shavit R, Dierickx C (2020) A new method for percutaneous drug delivery by thermo-mechanical fractional injury. Lasers Surg Med 52(1):61–69 CrossRef
26.
Zurück zum Zitat Hilerowicz Y, Friedman O, Zur E, Ziv R, Koren A, Salameh F et al (2020) Thermomechanical ablation-assisted photodynamic therapy for the treatment of acne vulgaris. A retrospective chart review of 30 patients. Lasers Surg Med. 52:966–70 CrossRef Hilerowicz Y, Friedman O, Zur E, Ziv R, Koren A, Salameh F et al (2020) Thermomechanical ablation-assisted photodynamic therapy for the treatment of acne vulgaris. A retrospective chart review of 30 patients. Lasers Surg Med. 52:966–70 CrossRef
27.
Zurück zum Zitat Artzi O, Koren A, Niv R, Mehrabi JN, Mashiah J, Friedman O (2020) A new approach in the treatment of pediatric hypertrophic burn scars: Tixel-associated topical triamcinolone acetonide and 5-fluorouracil delivery. J Cosmet Dermatol 19(1):131–134 CrossRef Artzi O, Koren A, Niv R, Mehrabi JN, Mashiah J, Friedman O (2020) A new approach in the treatment of pediatric hypertrophic burn scars: Tixel-associated topical triamcinolone acetonide and 5-fluorouracil delivery. J Cosmet Dermatol 19(1):131–134 CrossRef
28.
Zurück zum Zitat Friedman O, Koren A, Niv R, Mehrabi JN, Artzi O (2019) The toxic edge - a novel treatment for refractory erythema and flushing of rosacea. Lasers Surg Med 51(4):325–331 CrossRef Friedman O, Koren A, Niv R, Mehrabi JN, Artzi O (2019) The toxic edge - a novel treatment for refractory erythema and flushing of rosacea. Lasers Surg Med 51(4):325–331 CrossRef
Metadaten
Titel
Efficacy and safety of a thermal fractional skin rejuvenation system (Tixel) for the treatment of facial and/or scalp actinic keratoses
verfasst von
Meital Oren-Shabtai
Nadezhda Sloutsky
Moshe Lapidoth
Daniel Mimouni
Ilia Chorny
Igor Snast
Yael Anne Leshem
Rivka Friedland
Emmilia Hodak
Ifat Klein
Yael Agmon
Assi Levi
Publikationsdatum
12.04.2022
Verlag
Springer London
Erschienen in
Lasers in Medical Science
Print ISSN: 0268-8921
Elektronische ISSN: 1435-604X
DOI
https://doi.org/10.1007/s10103-022-03558-4